Search

Displaying results 5541 - 5550 of 8009 in total
  1. Drug

    AC-003

    go.drugbank.com/drugs/DB22691
    Investigational

    [L53458] It is being investigated for the treatment of acute graft-versus-host disease (GVHD) and idiopathic pulmonary fibrosis (IPF).[L53458] … [L53458,L53463] By inhibiting RIPK1 kinase activity, AC-003 thereby inhibits RIPK1-mediated cell death and inflammation.

  2. Drug

    TRO40303

    go.drugbank.com/drugs/DB16031
    Investigational

    TRO40303 is under investigation in clinical trial NCT01374321 (Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute

  3. Drug

    Brivanib

    go.drugbank.com/drugs/DB11958
    Investigational

    Brivanib is under investigation for the treatment of HepatoCellular Carcinoma. … Brivanib has been investigated for the treatment of Solid Tumors, Hepato Cellular Carcinoma (HCC), and Metastatic Colorectal Cancer (MCRC).

  4. Drug

    Apolizumab

    go.drugbank.com/drugs/DB06467
    Investigational

    Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.

  5. Drug

    BB-301

    go.drugbank.com/drugs/DB17011
    Investigational

    [A260112] Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).[L47062]

  6. Drug

    Enlonstobart

    go.drugbank.com/drugs/DB21890
    Investigational

    [A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.

  7. Drug

    Xanthine

    go.drugbank.com/drugs/DB02134
    Investigational

    The methylated xanthine compounds caffeine, theobromine, and theophylline and their derivatives are used in medicine for their bronchodilator effects. (Dorland, 28th ed) … It is an intermediate in the degradation of adenosine monophosphate to uric acid, being formed by oxidation of hypoxanthine.

  8. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). … The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).

  9. Drug

    Vapitadine

    go.drugbank.com/drugs/DB05738
    Experimental

    Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis

  10. Drug

    GTB-3550

    go.drugbank.com/drugs/DB18494
    Investigational

    GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form